Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 285

1.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

PMID:
17504993
[PubMed - indexed for MEDLINE]
Free Article
2.

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.

J Thorac Oncol. 2008 Aug;3(8):851-7. doi: 10.1097/JTO.0b013e318180477b.

PMID:
18670302
[PubMed - indexed for MEDLINE]
3.

[New diagnostic markers for malignant pleural mesothelioma].

Grigoriu BD, Grégoire M, Chahine B, Scherpereel A.

Bull Cancer. 2008 Feb;95(2):177-84. doi: 10.1684/bdc.2008.0576. Review. French.

PMID:
18304902
[PubMed - indexed for MEDLINE]
4.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
[PubMed - indexed for MEDLINE]
5.

Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.

Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.

J Thorac Oncol. 2011 Sep;6(9):1587-93. doi: 10.1097/JTO.0b013e31821e1c08.

PMID:
21642872
[PubMed - indexed for MEDLINE]
6.

Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.

Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A.

Clin Biochem. 2009 Jul;42(10-11):1046-50. doi: 10.1016/j.clinbiochem.2009.03.007. Epub 2009 Mar 18.

PMID:
19302997
[PubMed - indexed for MEDLINE]
7.

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K.

Lung Cancer. 2008 Aug;61(2):235-43. doi: 10.1016/j.lungcan.2007.12.025. Epub 2008 Feb 20.

PMID:
18281122
[PubMed - indexed for MEDLINE]
8.

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50. doi: 10.1158/1055-9965.EPI-08-0422. Epub 2009 Feb 3.

PMID:
19190155
[PubMed - indexed for MEDLINE]
Free Article
9.

[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].

Scherpereel A, Grigoriu BD, Astoul P.

Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S183-90. French.

PMID:
18971844
[PubMed - indexed for MEDLINE]
10.

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.

Lung Cancer. 2011 Oct;74(1):55-60. doi: 10.1016/j.lungcan.2011.02.007. Epub 2011 Mar 12.

PMID:
21397972
[PubMed - indexed for MEDLINE]
11.

Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.

Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A.

N Engl J Med. 2005 Oct 13;353(15):1564-73.

PMID:
16221779
[PubMed - indexed for MEDLINE]
Free Article
12.

Prognostic role of osteopontin expression in malignant pleural mesothelioma.

Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV, Papotti M.

Am J Clin Pathol. 2008 Jul;130(1):58-64. doi: 10.1309/TWCQV536WWRNEU51.

PMID:
18550471
[PubMed - indexed for MEDLINE]
Free Article
13.

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.

Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P.

Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60. Epub 2006 Feb 2.

PMID:
16456138
[PubMed - indexed for MEDLINE]
14.

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.

Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.

Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.

PMID:
18394747
[PubMed - indexed for MEDLINE]
15.

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.

Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.

Clin Chem Lab Med. 2011 Oct;49(10):1721-6. doi: 10.1515/CCLM.2011.242. Epub 2011 Jun 22.

PMID:
21692685
[PubMed - indexed for MEDLINE]
16.

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.

J Thorac Oncol. 2008 Nov;3(11):1317-24. doi: 10.1097/JTO.0b013e318187491c.

PMID:
18978568
[PubMed - indexed for MEDLINE]
17.

Sensitivity of urinary mesothelin in patients with malignant mesothelioma.

Creaney J, Musk AW, Robinson BW.

J Thorac Oncol. 2010 Sep;5(9):1461-6.

PMID:
20815094
[PubMed - indexed for MEDLINE]
18.

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.

Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O.

Clin Cancer Res. 2008 Mar 1;14(5):1431-7. doi: 10.1158/1078-0432.CCR-07-1613.

PMID:
18316566
[PubMed - indexed for MEDLINE]
Free Article
19.

Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.

Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L.

Int J Biol Markers. 2010 Jul-Sep;25(3):164-70.

PMID:
20878622
[PubMed - indexed for MEDLINE]
20.

Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.

Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW.

Chest. 2007 Oct;132(4):1239-46. Epub 2007 Jul 23.

PMID:
17646232
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk